Lifecore Biomedical (LFCR) Q1 2026 earnings summary

Executive summary

• Achieved 26% year-over-year revenue growth in Q3 2025 to $31.1 million, driven by increased demand, new business wins, and strong HA manufacturing and CDMO growth.

• Advanced late-stage pipeline with 11 programs targeting launches between 2026 and 2029, and signed multiple new customer programs expanding beyond ophthalmic therapeutics.

• Strengthened leadership and culture, implemented operational efficiencies, and achieved over 20% productivity gains in manufacturing.

• Completed a favorable FDA audit and five positive customer audits, including with a large multinational pharma.

• Fiscal year changed to align with the calendar year, effective May 26, 2025.

Financial highlights

• Q3 2025 revenue was $31.1 million, up from $24.7 million in the prior year period; fiscal 2025 revenues reached $128.9 million, up 0.5% year-over-year.

• Gross profit rose to $7.8 million from $5.4 million year-over-year, with gross margin improving to 25.0% from 21.8%.

• Net loss narrowed to $10 million ($0.29/share) from $16.2 million ($0.53/share) year-over-year; fiscal 2025 net loss was $38.7 million.

• Adjusted EBITDA improved to $3.1 million from negative $1.8 million year-over-year; fiscal 2025 Adjusted EBITDA was $19.5 million.

• SG&A expenses decreased by $5.9 million, reflecting cost control and legacy matter resolution; operating expenses declined 36% year-over-year.

Outlook and guidance

• Reaffirmed guidance for May 26–Dec 31, 2025: revenue of $74–$76 million, net loss of $16.4–$18.4 million, and Adjusted EBITDA of $12–$14 million.

• Q4 2025 revenue expected at $34–$36 million, with Adjusted EBITDA of $7–$9 million.

• Targeting 12%+ revenue CAGR and mid-term Adjusted EBITDA margins of 25%+.

• Revenue potential of ~$300 million annually in the mid-term, driven by expanded capacity and pipeline commercialization.

• Management expects operational improvements and a new ERP system in Q1 2026 to further enhance productivity and cost control.